Notas do episódio
Send us Fan Mail PBS listings can radically reshape practice and the August changes are all about precision. Rachael Babin from the Oncology Network sits down with Professor Craig Underhill to translate the latest Australian Pharmaceutical Benefits Scheme (PBS) oncology and haematology listings into what clinicians actually need: who’s eligible, what the key trials show and what to watch for once the script is written. We start with vorasidenib, newly listed for IDH mutant astrocytoma...
Site: oncologynetwork.com.au

